Moderna-Merck cancer vaccine data headline ESMO Day 2 in Madrid

At the ESMO conference in Madrid, Moderna and Merck presented highly anticipated data from their personalized cancer vaccine program, a key catalyst for both companies. The presentation, dubbed 'presidential' by observers, likely includes updated efficacy or safety results, though specifics are not detailed in the source. This matters because positive data could reshape the oncology treatment landscape and significantly impact the companies' valuations.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works